We administered AZD9291 at doses of 20 to 240 mg once daily in patients with advanced lung cancer who had radiologically documented disease progression after previous treatment with EGFR tyrosine ...
Treatment pattern and outcomes in patients with uncommon or compound EGFR mutations in India: CRSF 2020-03 study. This is an ASCO Meeting Abstract from the 2022 ASCO Annual Meeting I. This abstract ...
PFS benefit deepens with treatment duration: L858R patients treated through up to six cycles of LP-300 reached an 8.9-month median PFS, versus 8.4 months overall (n=15) – future patients will be ...
Adverse events in non-small cell lung cancer patients receiving immune checkpoint inhibitors: A single center, real-world study in China. This is an ASCO Meeting Abstract from the 2021 ASCO Annual ...
For many people with IgA nephropathy (IgAN), a condition in which immunoglobulin A (IgA) antibodies accumulate in the kidneys and trigger inflammation, kidney function stays stable for many years. For ...
The inclusion of race in eGFR calculations may lead to an overestimation of kidney function in Black individuals, potentially delaying necessary diagnosis and treatment for kidney disease. Recent ...
Doctors use estimated glomerular filtration rate (eGFR) scores to measure kidney functioning. African American people typically have higher eGFR scores than people of other ethnicities. People with ...
Epidermal growth factor receptor (EGFR) gene mutations are common biomarkers in non-small cell lung cancer (NSCLC). They affect about 1 in 3 people with NSCLC. About 90% of EGFR mutations are EGFR 19 ...
Lantern Pharma Reports HARMONIC™ Data Showing LP-300 Progression-Free Survival Benefit Deepens with Treatment Duration in EGFR Exon 21 L858R Lung Cancer Exon 21 L858R NSCLC Mutated Patients Treated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results